|
|
Vaccine Detail
|
RAS Peptide Cancer Vaccine TG01 |
| Vaccine Information |
- Vaccine Name: RAS Peptide Cancer Vaccine TG01
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: seven 17 amino acids long synthetic RAS oncogene-encoded peptides (NCIT_C200465)
- Immunization Route: subcutaneous injection
- Description: This is a cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. (NCIT_C200465) The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy. (NCT05638698)
|
| Host Response |
|
|
| References |
NCIT_C200465: RAS Peptide Cancer Vaccine TG01 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465]
NCT05638698: Tg01 Vaccine /​ Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) [https://clinicaltrials.gov/study/NCT05638698]
|
|
